Fiscal Tax Blog

Uncategorized

Five ways for Republicans to win on health care affordability

For most of the past 40 years, pollsters have asked voters: Which party do you trust more on health care? The answer has been pretty much the same over this whole period. Voters trust the Democrats more, and sometimes by a 2-1 margin. Republicans shouldn’t be afraid of the issue. Democrats have pretty much unilaterally designed the medical care system we have now. They own it. The outcome isn’t happy. We are getting spiraling costs with less access and, in…

Uncategorized

Republicans Can Win on Healthcare Affordability

For most of the last 40 years, pollsters have asked voters: Which party do you trust more on healthcare? The answer has been pretty much the same over this whole period. Voters trust Democrats more, sometimes by a two-to-one margin. When I’ve asked my Republican politicos why that is, the answer I typically receive is: Our party doesn’t do healthcare. Then they crouch in the fetal position. Well, the GOP certainly better start “doing healthcare,”…

Uncategorized

Insurance Scam

At Unleash Prosperity, our favorite word is “profit.” Profits make the world go round and are the best antidote to poverty. But when the business makes most of its profits off of government and taxpayer dollars, we’re not so excited. That’s the case with the $1.7 trillion health industrial complex, which is financed mostly through government subsidies. This chart shows that hospital earnings have doubled since 2015 (not adjusted for inflation). Profits are down in…

Uncategorized

Make Japan Pay Their Fair Share for Drugs, Mr. President

Donald Trump will soon meet with Japanese Prime Minister Sanae Takaichi. Near the top of the agenda should be an effort to secure a pledge from her to ease Japan’s price controls on US-made brand drugs. UP senior fellow Tomas Philipson makes a compelling case in the Washington Examiner: For decades, Japan, the world’s fifth-largest economy, has artificially suppressed its spending on innovative medicines, effectively freeriding on U.S. rewards for innovation… That free-riding is unfair. But…

Uncategorized

Drug pricing should be near top of agenda at Trump-Takaichi meeting

President Donald Trump will soon host Japanese Prime Minister Sanae Takaichi at the White House, where the two leaders will seek to strengthen the United States-Japan alliance and boost both countries’ economies. The president can advance these goals simultaneously in healthcare by urging Takaichi to reform how her aging nation’s healthcare system pays for prescription drugs. For decades, Japan, the world’s fifth-largest economy, has artificially suppressed its spending on innovative medicines, effectively freeriding on U.S. rewards for innovation. The country’s government-run health system conducts annual pricing reviews and…

Uncategorized

Trump’s ‘most favored nation’ policy threatens US competitiveness with China

Congressional enactment of the “most favored nation” drug pricing policy urged by President Donald Trump in his State of the Union message would gravely harm American innovation, competitiveness, and national security in the emerging pharmaceutical technology race with China by crippling the market incentive system that has reliably propelled U.S. global leadership in this vital sector for decades. MFN policies are price-control schemes that establish caps on the costs of prescription drugs sold in the United States based on…

Uncategorized

Seniors Paid Billions in Extra Premiums Due to Alleged Medicare Overpayments

The average American senior’s Medicare premiums last year were about 10% higher, or more than $200 annually, because of alleged overpayments to private Medicare Advantage plans, congressional investigators found. Medicare Part B premiums that most seniors pay were partly pushed up by controversial health-insurer practices such as adding diagnoses to trigger higher payments, according to the Joint Economic Committee, a bipartisan group of lawmakers that advises Congress on financial matters.

Uncategorized

Could U.S. policy clinch China’s grip on biotech?

Health care policy often carries unintended consequences. The Inflation Reduction Act’s “pill penalty,” for example, gave small-molecule drugs — which often take the form of pills — a shorter window of exemption from Medicare price-setting than biologics, which investors say disincentivizes innovation in small-molecule medicines that have the potential to treat cancer, neurological diseases, and more. Another IRA provision limited price-negotiation exemptions only to orphan drugs approved to treat a single rare disease, discouraging follow-on…